Lisata Therapeutics announced the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to LSTA1, the Company’s lead product candidate, for the treatment of malignant glioma. “Malignant glioma is one of the most aggressive and deadly malignancies,” stated Kristen Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. “This Orphan Drug Designation acknowledges the high unmet medical need of this patient population as well as the potential of LSTA1 to benefit patients in this setting.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LSTA:
- Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
- Lisata Therapeutics malignant glioma treatment granted FDA orphan status
- Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
- Lisata Therapeutics announces retirement of Ruoslahti from board of directors
- Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference